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Triple-negative breast cancer (TNBC) is characterized by the absence of expression of the 
estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 
(HER2). Therefore, TNBC is unresponsive to targeted hormonal therapies, which limits 
treatment options to nonselective chemotherapeutic agents. Basal-like breast cancers 
(BLBCs) represent a subset of about 70% of TNBCs, more frequently affecting younger 
patients, being more prevalent in African-American women and significantly more 
aggressive than tumors of other molecular subtypes, with high rates of proliferation and 
extremely poor clinical outcomes. Proper classification of BLBCs using current 
pathological tools has been a major challenge.  Although TNBCs have many BLBC 
characteristics, the relationship between clinically defined TNBC and the gene expression 
profile of BLBC is not fully examined. The purpose of this study is to assemble publicly-
available TNBC gene expression datasets generated by Affymetrix gene chips and define 
a set of genes, or gene signature, that can classify TNBC samples between BLBC and Non-
BLBC subtypes. We compiled over 3,500 breast cancer gene expression profiles from 
several individual publicly available datasets and extracted Affymetrix gene expression 
data for 580 TNBC cases. Several popular data mining methods along with dimensionality 
reduction and feature selection techniques were applied to the resultant dataset to build 
	 iv	
predictive models to understand molecular characteristics and mechanisms associated 
with BLBCs and to classify them more accurately according to important features extracted 
through microarray data analysis of BLBC and Non-BLBC cases. Our result can lead to 
proper identification and diagnosis of BLBCs, which can potentially direct clinical 
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	 Triple-negative breast cancer (TNBC) constitutes approximately 20%-25% of all 
breast cancer cases with poor prognosis.1 TNBC is defined as the lack of specific breast-
cancer-associated receptors, mainly progesterone (PR), estrogen (ER), and human 
epidermal growth factor (HER2). As a result, due to the lack of targets TNBC is 
unresponsive to targeted hormonal therapies, which limits treatment options to 
nonselective chemotherapeutic agents.2  
Recent technological advances allow for high throughput profiling of biological systems 
at the molecular level in a cost-efficient manner. The relatively low cost of data generation 
is leading us to the "Big Data Era". Today big data can be created out of small data and the 
combination of datasets from various sources is a major aspect of “big data”. The 
availability of such large datasets provides unprecedented opportunities for data mining, 
deep learning, and integrative analysis over various layers of data which set the goal to link 
all the molecular information and translate it back into meaningful information in precision 
medicine, systems biology, molecular physiology or pathophysiology.  
Translational modeling is not new to cancer research. Predictive modeling has been applied 
in clinical domains and into a wide variety of problems in breast cancer such as 






diagnosis3,survivability4, prognosis5, susceptibility6 and recurrence7. However, the extent 
to which microarray data can improve the diagnosis of BLBC cancer has not been fully 
examined. 
	 The purpose of this analysis is to assemble publicly-available TNBC gene 
expression datasets generated on Affymetrix gene chips and define a set of genes, or gene 
signature, that can classify TNBC between the basal-like breast cancer (BLBC) and Non-
basal-like breast cancer (Non-BLBC) subtypes. A proper diagnosis of BLBC will have 
clinical implications by dictating the most effective therapy.    
	 The approach that used to characterize basal-like triple negative breast cancer is 
data mining approach using supervised analysis (i.e., classification). Eight data mining 
techniques were used to classify basal-like triple negative breast cancer include Neural 
Network, Decision tree, Logistic Regression, Support Vector Machine, Least Angle 
Regression, Gradient, Random Forrest, and Bayesian Classifier.  















  Background 
Breast Cancer (BC) 
 
Environmental and genetic factors are the main causes of Breast Cancer (BC), due to the 
accumulation of mutations in essential genes.8 In developed countries, BC is the most 
common cancer in women, being the cause of death in approximately 20% of females 
diagnosed.9 In the case of African-American women under the age of 50 years of age 39% 
of the diagnosed BC cases are of the TNBC type, while they only represent 16% in 
Caucasian women.10 Based on global gene expression analyses, four molecular subtypes 
of BC have been identified, mainly, luminal A, luminal B, HER2-enriched and basal-like. 
These subtypes have shown to be significantly different in terms of their baseline 
prognosis, age at diagnosis, risk factors and response to therapies. Among these types, 
basal-like breast cancer is of great interest to investigators and clinicians due to its poor 
prognosis, high frequency, limited targeted therapies.11  
 
Triple Negative Breast Cancer (TNBC) 
 
TNBC is defined as a type of BC which shows the absence of the three common BC 
biomarkers, PR, ER, and HER2.12 TNBC tends to be more aggressive compared to other 
BC types. In addition, the chance of early recurrence is high, due to the absence of the 
ER.13 











The absence of the BC-specific targets ER, PR, and HER2, limits the treatment options for 
TNBC. These include hormone therapies, anti-HER2 targeted therapies, endocrine 
(tamoxifen, aromatase inhibitor inhibitors) therapy, and trastuzumab (anti-HER2). TNBC 
cases only achieve 19% clinical-complete-response to chemotherapy.14 This leaves as the 
only treatment option available for TNBC, cytotoxic chemotherapy.15 
Although TNBC has many BLBC characteristics, the relationship based on the gene 
expression is not completely clear, where not all TNBC cases fall into the BLBC subtype.16 
 
Basal-like Breast Cancer (BLBC)  
 
BLBC represents approximately 15-20% of breast cancer cases,17 and is defined as being 
ER negative, PR negative, cytokeratin 5/6 positive and/or HER2 positive.18 It mainly 
occurs at an early age, showing an aggressive clinical outcome, presence of distant 
metastases, especially within the first five years after the diagnosis, showing poor 
prognosis, and a high mortality rate.  
 
BLBC subtype of TNBC 
Based on the protein profile, 53-84% of TNBC cases are diagnosed as BLBC.19 Another 
study reported that 6 of 31 (19.4%) triple- negative breast tumors were classified as Non-












BLBC, while 15 out of 207 (6.3%) non-triple-negative tumors showed basal cytokeratin 
biomarkers.20 A previous investigation showed that 69.7% of TNBC were classified as 
BLBC.21 Until now, there is no accepted definition to classify BLBC. To improve the 
criteria for defining BLBC, some studies included microarray-based expression profiling 
data, and panels of immunohistochemical surrogates, which yielded a definition that 
included cancer tissue (1) with the absence of ER, PR, and HER2 expression (i.e., triple-
negative); (2) expressing one or more high-molecular-weight/basal cytokeratin (i.e., 
CK5/6, CK14, or CK17), which are usually expressed in the basal epithelial layer of skin 
and airways, but are also expressed in some breast carcinomas; (3) absence of ER and 
HER2 expression in conjunction with CK5/6 and or epidermal growth factor EGFR; (4) 
absence of ER, PR, and HER2 expression in conjunction with CK5/6 and/or EGFR.22  
 
Diagnostic Difficulties   
 
Unlike other subtypes of BC, the BLBC subtype seems not to correlate with the size of the 
primary tumor and the presence of regional lymph node metastases.23 However, there are 
a variety of immunohistochemical markers that can be used to identify BLBC, such as 
cytokeratins (CK5/6, CK14 or CK17), EGFR, smooth muscle actin (SMA), p63, p-
cadherin, ki-67, p53 or c-kit antigen with concomitant lack of ER, PR, HER2 and “luminal” 
cytokertins (CK8, CK18, CK19) expression.24 BLBC shows higher genome instability 
compared to other BC subtypes. Therefore, there is no particular set of markers that 









explicitly define BLBC.25 However, a more detailed classification of TNBC tumors needs 
to be established because of the variability shown within this type based on molecular 
studies26. Moreover, to define better prognostic biomarkers and therapeutic alternatives, 
further investigations are needed to better classify TNBC, BLBC, and Non-BLBC tumors.   
 
Biomarkers in TNBC and BLBC 
 
A biomarker is a biological molecule that serves as a sign for normal biological processes 
or conditions or signals the presence of an abnormal process, condition, and thus, the 
presence of a biological defect, risk to a particular ailment, or an actual disease. 
Researchers have explored biomarkers for selected types of cancer to aid in prevention or 
risk assessment, diagnostic, and treatment or management27. Nonetheless, the existing 
body of literature remains unorganized when it comes to biomarkers for more specific types 
of cancer, such as in the case of TNBC as BLBC, TNBC as Non-BLBC, or Non-TNBC as 
BLBC. 
Two of the earliest identified biomarkers for general breast cancer are BRCA1 and 
BRCA2, which are related tumor suppressor genes responsible for repairing DNA or 
destroying cells if DNA damage is irreparable. Damage in either of these two genes, due 
to specific heritable mutations, increases the risk of cancer in breast tissue, as well as in 
ovarian and blood tissue due to the loss DNA repair capacity28 Although, both BRCA1 and 
BRCA2 are important biomarkers for susceptibility to breast and other types of cancer, 









their capacity in defining susceptibility and presence of TNBC and BLBC, has been very 
limited.   
Several review studies have identified other alternative biomarkers. For instance, one 
study29 did a comprehensive review of PubMed and conference databases to evaluate the 
literature concerning TNBC biomarkers. The study listed the following biomarkers: 
epidermal growth factor receptor (EGFR), vascular endothelial growth factor, c-Myc, C-
kit, basal cytokeratins, poly(ADP-ribose) polymerase-1, p53, tyrosinase kinases, m-TOR, 
heat and shock proteins, and TOP-2A. The same study30 noted that the absence of estrogen 
receptors or ER, progesterone receptors or PR, and HER-2/neu receptors are distinctive 
biomarkers for BLBC and they represent 80% of TNBC cases. Other studies31 have 
identified additional biomarkers for BLBC, including EGFR and cytokeratin CK 5/6, 
which are keratin proteins that serve as essential components of intermediate filaments that 
help cells resist mechanical stress. 
It is also important to note the differential expression of other keratin proteins is also seen 
in both TNBC and BLBC. For instance, the differential expression of CK7, CK8, CK18, 
and CK19 was observed in more than 90 percent of all breast carcinomas. In addition, the 
expression of CK5/6, CK14, and CK20 positively correlated with a high tumor grade.32 
Another study33 that analyzed  11 TNBC tumors, identified the specific occurrence of 











keratins. For example, eight of the tumors were positive for basal markers, CK5 and CK17, 
six of which also were also positive for CK14. The study concluded that the use of 
combination immunohistochemistry, which included CK5, CK14, and CK17, could 
contribute to the detection of basal-like carcinoma. 
Overexpression of the protein-coding gene ID4, which is associated with the regulation of 
many cellular processes during both prenatal development and tumorigenesis, and TP53, 
which prevents cancer formation through tumor suppression and genome mutation 
prevention, have been linked to BLBC. The high expression of Ki67 mRNA has also been 
associated with the high proliferation of BLBC subtype.34 Note that this nuclear protein 
has been suggested to play a necessary role in cellular proliferation, as well as in the 
ribosomal RNA transcription. 
Other biomarkers have been identified to indicate both prognosis and therapeutic response 
to TNBC and BLBC. For example, secreted frizzled related protein 1 or SFRP1 has been 
found to be a potential molecular marker for response to chemotherapy and potential 
prognostic marker35 and an increased secretion of this protein has been associated with 
higher expression in basal-like cancer cell lines. Thus, one study concluded that SFRP1 is 
correlated with both an aggressive form of breast cancer and positive response to 
neoadjuvant chemotherapy.36 










Another notable example centers on the interplay between two genes that are both 
indicative of cancer development and prognosis. For instance, one study37 revealed that 
microRNA-26 appears to inhibit the metastasis of TNBC, by targeting transmembrane 4 
L6 family member 1 or TM4SF1. Note that TM4SF1 expression in breast cancer tissues is 
higher than that in adjacent normal breast tissues. Furthermore, the expression level of 
TM4SF1 in MDA-MB-231 cells was associated with the metastatic tendency of TNBC. 
Nonetheless, the overexpression of miR-206 in the same MDA-MB-231 cells appears to 
down-regulate TM4SF1. 
The interplay with forkhead box C1 or FOXC1 and chemokine receptor-4 or CXRC4, also 
affect TNBC and BLBC prognosis and metastasis. Specifically, FOXC1 overexpression 
boosts TNBC metastasis by activating the transcription of CXRC4. However, in a zebrafish 
tumor model, either AMD3100 or siRNA in MDA-MB-231 cells can inhibit CXRC4 by 
under-expressing FOXC1.38 
Moreover, primary breast cancer tissues and its derived cell lines and, particularly, in 
TNBC tissues and cell lines have up-regulated microRNA-761. The overexpression of 
exogenous microRNA-761 augmented the TNBC cell proliferation, colony formation, 
migration, and invasion in vivo. Essentially, microRNA-761 represses the expression of 
TRIM29, thus inducing aggressive phenotypes in TNBC cells. On the other hand, the 
overexpression of TRIM29 reversed the proliferative and invasive capacities of TNBC 








cells39. Note that microRNA-761 is a non-coding RNA that affects the translation and 
stability of mRNAs. TRIM29 or tripartite motif-containing protein 2 encodes a gene 
belonging to the TRIM protein family and may act as a regulatory factor involved in 
carcinogenesis and/or differentiation. However, a high level of another TRIM protein 
known as TRIM28 with TNBC. The down-regulation and depletion of this protein reduced 
the ability of TNBC cells to induce tumor growth when injected subcutaneously, thereby 
resulting in a significant reduction of tumor growth.40 
Another gene linked to the proliferation of cancerous mammary cells is actin-related 
protein 2/3 complex or ARPC2. One study41 screened the Oncomine database and found 
micro-profiling studies that linked the overexpression of ARPC2 proteins to cancerous cell 
lines. Furthermore, they found a unique link between ARCP2 overexpression and invasion, 
apoptosis, and proliferation of mammary carcinoma cells, including tumor size, lymph 
node metastasis, tumor grade, poor prognosis and response to treatment. Another study42 
showed that that the up-regulation of stearoyl-CoA desaturase 1 or SCD1 was associated 
with shorter survival in breast cancer patients. A study43 of specific TNBC subtypes, noted 
that SCD1 inhibition had been reported to reduce the proliferation and survival of cancer 
cells, thereby suggesting a new targeted therapeutic approach. 















The mRNA expressions of several S100 family of genes have been associated with 
malignancies in human breast tissue. In the case of TNBC, an analysis44 using the Kaplan-
Meier plotter database revealed that S100P expression is significantly associated with poor 
survival in TNBC patients. The abundance of mRNA S100P is indicative of poor overall 
survival of these patients. Another study45 involved silencing the pi subunit of the 
GABA(A) receptor or GABRP in vitro. Results revealed a decreased GABRP tumorigenic 
potential and migration to be concurrent with alterations in the cytoskeleton of basal-like 
cell lines, by reducing cellular protrusions and expression of several cytokeratin proteins 
related with BLBC, such as KRT5, KRT6B, KRT14, and KRT17.  
The identification of genetic biomarkers for TNBC and BLBC should involve considering 
the following three points. First, focus on genes that can determine the existence and early-
stage development of TNBC and BLBC. Examples of these genes include the under-
expressed BRCA1 and BRCA2 tumor suppressor genes, as well as the under-expressed 
ER, PR, and HER2 receptors.46 47 Also, overexpressed keratin proteins EGPR, ID4, TP53, 
and Ki67 have been linked to TNBC and BLBC as well.48 
Second, look for genetic biomarkers that can determine the progression or prognosis, 
therapeutic response, and overall survivability to TNBC and BLBC. As an example49, 
SFRP1 secretion which correlates with both an aggressive form of breast cancer, has 












responded positively to neoadjuvant chemotherapy. Other examples include TM4SF1 in 
MDA-MB-231 cells, FOXC1, CXRC4, microRNA-761, ARPC2, and SCD1 all of which 
are overexpressed in aggressive tumors, and those with a higher likelihood of cellular 
migration resulting in metastasis, and low survival.50 
Third, identify genetic biomarkers responsible for the development and progression of 
TNBC and BLBC, which can also lead to the development of targeted therapeutics. One 
notable example51 is SCD1 inhibition that has been reported to reduce the proliferation and 
survival of cancer cells. Another is down-regulation and depletion of TRIM28, which has 
shown reduction in tumor growth.52 In vivo studies also showed that expression of 
AMD3100 or siRNA in MDA-MB-231 could inhibit CXRC4 by under-expressing FOXC, 
thus controlling proliferation and metastasis.53 
 
Gene Expression Profiling 
 
DNA microarray technology has been commonly used in many biological purposes such 
as gene expression analysis, environmental monitoring, disease characterization. Its 
application in gene expression profiling is based on a multiplex technology used to 
simultaneously access thousands of genes and identify genes who are differentially 
expressed in response to “pathogens” by comparing gene expression between infected and 
uninfected cells or tissues.54 A DNA microarray chip consist of an arrayed series of 
microscopic spots with immobilized gene-specific DNA oligonucleotides probes. The 







hybridization of the fluorophore-labeled target onto the probe is usually detected and 
quantified to determine relative abundance of target.55  
In Affymetrix microarrays, the probes are attached to the substrates by a covalent bond 
through a photolithographic process. Each GeneChip contains around 1,000,000 probe sets 
that are intended to measure expression for a specific mRNA. Each probe set consists of 
probe pairs selected from the target sequence which is derived from one or more mRNA 
sequences. The first pair is a perfect match (PM), and the other is mismatch (MM) at the 
center. This allow the quantitation and subtraction of nonspecific signals cross-
hybridization.56 Each gene or transcript consists of 11 probe pairs on the GeneChip, each 
name of which has a suffix consisting of the last three or four characters of its name that 
describes their ability to bind different genes, splice variants, or their uniqueness as it 
shown below57:  
• “_at” hybridizes to unique anti-sense transcript of the gene. 
• “_a_at” all probes cross-hybridize to the same set of sequences from the same gene 
family. 
• “_s_at” all probes cross-hybridize to the same set of sequences, but these sequences are 
not from the same gene family.  
• “_x_at” at least one probe cross-hybridize with other target sequences.  
Microarray technology has been used, since its early development, to identify gene 
expression profiles of clinical breast cancer cell lines and specimens. Some of the breast 





cancer sub-groups that have been identified using this technology are the basal sub-type, 
and normal-like, luminal A, luminal B, and ERBB2 over-expressing.58    
Data Mining in Gene Expression 
Data mining can be used with gene expression data to discover patterns and develop 
knowledge from biological databases using information technology and computational 
techniques. Data mining is an automated data analysis process to find relationships among 
data elements. Many of these relationships are not obvious due to the large amount of the 
data. Therefore, the researches and scientists can use the data mining techniques to extract 
useful information and create knowledge from data to identify correlations between 
elements.59   
The most common types of microarray data analysis in data mining includes gene selection, 
clustering, and classification60. The method of analysis can be determined depending on 
the nature of the data and the desired knowledge, using either a descriptive or predictive 
model. A descriptive model is used to identify patterns and relationships among the data, 
while a predictive model is used to predict the data using existing patterns.  
There are several data mining software that can be used to perform data mining, such as 
SAS Enterprise Miner, S-Plus, SPSS, IBM Intelligent Miner, SGI MineSet, Microsoft SQL 
Server 2000, and Inxight VizServer. However, some biological data mining tools have been 
developed, such as Statistics for Microarray Analysis, Affymetrix Data Mining, 







GeneSpring, VectorNTI, Spot Fire, and COMPASS.61 However, in our study SAS 
Enterprise Miner software will be used to perform data mining analysis. 
SAS Enterprise Miner 
SAS Enterprise Miner software is an advanced tool to help users to perform data mining 
by developing either descriptive or predictive models. SAS software provides a variety of 
data mining tasks, including decision tree, neural networks, link analysis, and linear and 
logistic regression.62   
Classification  
In this study, classification task will be used to perform data mining, which is a process of 
learning a function that classifies a data element into two or several classes. Classification 
is mostly used in microarray analysis to distinguish diseases or identify the most efficient 
treatment for given genetic signature or predict outcomes by performing a predictive model 
based on known gene expression patterns.63 
The most popular microarray data mining methods for classification include Support 
Vector Machine (SVMs), Neural Networks, K-nearest neighbors, classification/Decision 
trees, voted classification, weighted gene voting, and Bayesian classification.64 However, 
in this study, Artificial Neural Network, Logistic Regression, Decision Tree, Least Angle 







Regression, Bayesian classifier, Gradient Boosting, SVMs, and Random Forrest models 
were investigated. 
            Artificial Neural Networks 
 
Artificial Neural Networks (ANNs) are known as “massively parallel processors, 
which tend to preserve experimental knowledge and enable their further use”.65 
This model was created based on learning the processes of the neurological function 
of the brain and the cognitive system.66 ANNs can provide an extreme complexity 
of non-linear functions and predict new observations. The advantage of the parallel 
computing environment of ANNs allows users to improve the predictive power 
algorithm.67 Applying neural networks enables users to build models with 
significantly more lift by allowing more runs to enhance predictive power 
incrementally. Additional features of this model include smart defaults for most 
neural network parameters, automatic selection of a validation data group, and 
automatic standardization of input data and targeted variables.68 
 
            Logistic Regression 
 
Logistic regression is a statistical method used to analyze database to classify cases 
into the most likely category based on one or more independent variables. In this 
study, linear regression cannot be applied since the response variable is discrete. 








Therefore, the regression will predict the odds of its occurrence into two categories 
instead of predicting the estimation point.  Some of the advantages of using Logistic 
Regression includes selecting variables and modeling capabilities for unordered 
multinomial data.69  
 
            Decision Tree 
 
Decision tree is a classification algorithm starts with a single node, which branches 
into possible class predictions the size of the decision tree and classification 
accuracy are used to determine the quality of the model analysis. Decision tree uses 
mathematical algorithms to identify a variable, also to corresponding threshold for 
that identified variable, which is branches the input data into two or more 
subgroups. The process is repeated at each node until the tree fully construed. The 
spilt search algorithm uses corresponding threshold to maximize the homogeneity 
of the outcome subgroups. The most common mathematical algorithm that used to 
split the observations into multiple classes are entropy-based information gain, Gini 
index, and Chi-square test.70 Finally, the complexity of the tree is optimized via 
pruning between training and validation sets. Advantages of Decision trees include 
ease of deployment, interpretation and visualization. 
 
            Random Forest 
 




Random Forest is a collection of multiple Decision trees. It is a supervised learning 
algorithm that draws random samples from the training dataset to grow the trees of 
the forest to the largest extent possible. Trees are trained in parallel and no pruning 
is carried out to reduce the size of the trees. In order to categorize new data, it is 
first inputted to each of the trees to generate classifications or votes based on the 
selected variables. The Random Forest then chooses the final classification 
outcome based on the votes scored among all the trees. Some of the advantages of 
using Random Forest includes high accuracy, ability to handle large volumes of 
multidimensional data, and effective imputation of missing data among others.71 
 
            Support Vector Machine 
 
Support Vector Machine (SVM) is a class of machine learning algorithms that 
enables users to fit a discriminant function of features such as polynomial and 
sigmoid nonlinear kernels to separate one class from another. The nonlinear kernel 
transforms the input data to a high dimensional space such that the data space 
become separable using two parallel separating hyperplanes. The distance between 
the parallel hyperplanes is maximized to the extent in which an optimized 
classification model can be realized. An SVM model can also be used for outlier 
detection and regression. Some of the SVM’s advantages include effective handling 
of unbalanced data and less complexity compared to other classifiers such as ANNs 
Previous research has reported that SVM can provide diagnosis ability with high 
accuracy in cancer prediction.72 





            Least Angle Regression  
 
Least Angle Regression (LARS) belongs to a family of generalized linear models 
designed to handle high-dimensional data. The algorithm uses a forward stepwise 
selection method to identify the optimal variable set; however, instead of adding 
variables at each step based on some pre-specified criteria such as adjusted R2 or 
Akaike, it selects the variable that is most correlated with the target variable and 
then increases the estimated parameters in the least-squares direction until another 
variable has as much correlation with the target as the current one has. This 
selection process is repeated until none remain to be chosen. Some 
major advantages of LARS method are its abilities to handle high dimensional 
multi-collinear data and identify the best set of variables. 73 
 
            Bayesian Classifier 
      
Bayesian Classifiers are a family of simple probabilistic models that rely on Bayes’ 
theorem to make class predictions given some data. In Bayesian machine learning, 
the input variables are assumed to be independent from each other. To classify a 
new observation, it simply estimates the probability that the given data point falls 
in a certain class and at the end, chooses the classification that has the highest 
probability. Some of the advantages of using a Bayesian Classifier model includes 
handling continuous and discrete data, making probabilistic predictions, and 
requiring less training data. 




            Gradient Boosting 
 
Gradient Boosting is a supervised machine learning algorithm for classification and 
regression applications. It is an ensemble of many prediction models using decision 
trees. Unlike Random Forest that uses random samples to build independent trees 
in parallel, Gradient Boosting builds trees one at a time in a sequential manner such 
that each tree is dependent on the residuals of the previous one. Gradient Boosting 
first draws a random sample (with replacement) from the original data, trains a 
decision tree, and tests its performance on the entire data. Then, the next random 
sample is drawn from the original dataset, which includes data points that were 
misclassified with the previous tree, and used that to build the second tree, and so 
on. This process is repeated until the error function does not change. While Gradient 
Boosting provides a very high predictive accuracy, it is less interpretable and prone 
to over-fitting due to its greater flexibility in fitting data.74 
 
 
Data Pre-processing  
 
Data pre-processing for data mining is a critical step to get better results. The data pre-
processing is a process of cleaning the data from missing, out of range, or invalid values. 
It also provides several features such as understanding what the data represents, exploring 
variable statistics and distributions, performing appropriate transformations, and reducing 
the data among others. However, data pre-processing is time-consuming, but it is an 
                                                
74	Zolbanin	H.M,	150-161.	
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important step to ensure the accuracy of the final results. Data pre-processing takes 
approximately up to 80% of the overall time of data mining.75 
 
 
Measures for Performance Evaluation 
 
There are three common performance measures used in binary classification models. The 
first is accuracy which determines the overall classification performance of the model; it 
calculates the percentage of correctly classified instances. Second, sensitivity which 
measures the proposition of positives that correctly identified. The third is specificity which 
measures the proposition of negatives that correctly identified. These performance 
measures can be obtained mathematically by the following expressions:  
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 = 	
𝑇𝑃 + 𝑇𝑁










TP, TN, FP, and FN represent True Positive, True Negative, False Positive, and False 
Negative, respectively.76 Some studies use the misclassification rate to evaluate 
performance accuracy. However, the SAS Enterprise Miner software uses the 










A literature survey showed that there are many studies on the characterizing basal-like 
breast cancer using statistical analysis. However, we could only find a few studies related 
to characterizing BLBC using data mining approaches.  
Rody et al.77 conducted a research study regarding TNBC and BLBC by using a database 
generated on Affymetrix gene chips for 579 TNBC to perform unsupervised analysis to 
propose a definition of metagenes that differentiate molecular subset within TBNC without 
considering any clinical outcome. A single platform (Affymetrix U133a AND u133 Plus 
2.0 chips) was used for data. However, 394 cases used for discovery, while 185 cases for 
validation. 16 metagenes expressions were correlated with survival and multivariate 
analysis, including pathological and routine clinical. Those metagenes includes basal-like 
phenotype, apocrine/androgen and cludin-low molecular subtypes, or reflected various 
non-neoplastic cell population, including blood, stroma, immune cells, adipocytes, 
inflammation and angiogenesis within the cancer.  
In this study, Rody et al. observed a transparent bimodal distribution of basal-like metagene 
score within TNBC. Based on the bimodal distribution, a cutoff (0.0014) was driven to 
separate cases into low and high expressions groups by fitting two normal distributions as 
shown in Figure 1. As a result, 72.8% of TNBC were classified as BLBC in the discovery 
cases, while 69.7% of in validation cases.   
 In our study, we used the same TNBC database, and the cutoff value (0.0014) of 
BLBC to average the important variables. We defined relevant genes from the data as the 
average expression of high co-expressed genes groups without considering clinical 
outcomes.  





Figure 1. Distribution of the expression of basal-like metagene among TNBC.78 
Methodology 
It is widely known among data scientists that big data is composed of not only a large 
volume of data but also from several different sources, in various formats, from which 
greater insights can be gleaned. Therefore, a considerable amount of time and effort needs 
to be devoted on data management. Moreover, recent development in high performance 
analytical methods has improved our ability to extract meaningful insights from high 
dimensional data, which can be investigated using statistical analysis. In this section, we 
discuss how these important tasks are accomplished.  We describe the data and research 
methodology used in this study in the following subsections. Our research methodology 
consists of four major phases: data acquisition, data integration, data preprocessing, and 
predictive modeling. The analytical methodology is depicted in Figure 2. 
































Figure 2. Research Methodology. 
 
However, it is important to mention that other prognostic factors in BC such as age, 
histological grade, and tumor size were not considered. The grade has no significant 
regard of prognosis since most TNBC cases are high grade. Also age and tumor size 
factors are not considered since TNBC subtype is associated with younger age, so the 
impact of these two factors for prognosis in TNBC is not yet fully clear.79  
 
                                                
79	Rody,	2011	
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Data Acquisition and Integration 
Microarray data generation is a very expensive process; therefore, collecting large data 
microarray is challenging and requires a substantial amount of resources. To build a large 
sample size for this study, it was necessary to pool several datasets from different 
laboratories.80 We used multiple public datasets that were built according to the most 
widely microarray platform (Affymetrix U133A and U133 Plus 2.0 chips) and included 
only cases that were defined as triple negative based on the mRNA expression of ER, PgR, 
and HER2 as previously described.81 We compiled a total of 3,488 publicly available breast 
cancer gene expression profiles from 28 individual datasets and extracted Affymetrix gene 
expression data for 579 TNBC cases.  
 
Data Preprocessing  
Data preprocessing is a critical step in data mining, which involves data cleaning, variable 
reduction and feature selection. It involves cleaning the data from missing, out of range, or 
invalid values. It also allows for a better understanding of what the data represents, to 
explore variable statistics and distributions, to perform appropriate transformations, and to 
reduce the data, among others. Although data preprocessing is time consuming, it is an 
important step in ensuring the accuracy of the results. Data preprocessing takes up to 80% 
of the overall time of data mining.  
 




With microarray data being high dimensional, characterized by many variables and few 
observations, it requires feature selection and dimension reduction techniques to remove 
genes that do not provide significant incremental information. In this study, we observed 
five missing genes in some of the expression datasets, so we excluded those genes from 
the analysis. Moreover, we applied various feature selection methods, such as chi-square, 
decision tree, Least Angle Regression/ Least Shrinkage and Selection Operator 
(LARS/LASSO), principle component analysis (PCA) and ensemble (multi-method) 
algorithms, to identify key variables (genes) that could explain the differences in the 
observations and could be used to simplify the analysis and prediction of BLBCs. It is 
recognized that different feature selection techniques may result in different sets of 
biomarkers, that is, different groups of genes highly correlated to a given condition; 
however, together, these results can be used to identify driving pathways in basal-like 
breast cancer.       
 
Predictive Models 
In this study, we used five different feature selection methods (i.e., Chi-square, tree, LARS, 
LASSO and ensemble), along with eight predictive models (i.e., Logistic Regression, 
Decision tree, Random Forest, Support Vector Machine, Neural Networks, LARS, 
Gradient Boosting, and Bayesian Classifier) in an empirical investigation to understand, 
characterize and predict BLBCs. The data was divided into 70% for training and 30% for 
validation. We performed supervised analysis to define a set of gene markers that 
distinguished molecular subsets within TNBCs. The 574 cases were divided into 394 for 
discovery and 185 for validation. The initial step was to build stratified datasets for this 
analysis. The second step involved applying various popular data mining techniques, 
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including Decision trees, Regression analysis, Random Forest, Neural Network, Least 
Angle Regression, Bayesian Classifier, Gradient Boosting, and Support Vector Machine, 
to classify BLBC and non-BLBC cases and to identify structures in the molecular data of 
the targeted disease. Of all the cases evaluated, 394 were used for training and 185 for 
validation. More than 22,000 genes expression data were correlated with survival using 
multivariate analysis, including pathological and routine clinical data. Those metagenes 
included the basal-like phenotype, apocrine/androgen and claudin-low molecular subtypes, 
or reflected various non-neoplastic cell populations, including blood, stroma, immune 
cells, adipocytes, inflammation and angiogenesis within the cancer. In summary, 40 
different predictive models were built to identify gene signatures and determine which 
genes contribute most to BLBC.  
 
We used two types of prediction models in SAS enterprise Miner 12.3 software. The first 
type is partial data, which allows us to divide the data set for two groups, 70% for the 
data used for train, and 30% for validation. Thus, 579 TNBC cases divided into 394 cases 
for the discovery cohort and 185 cases for validation. High-performance data partition 
used train data for preliminary model fitting, whereas Validation data used to assess the 
adequacy of the fitted model.82  
The other type is high-performance data mining (HPDM), which provides several 
advantages, including reductions of dimensions for structured inputs and perform 
unsupervised variable selection. The high-performance regression aims to predict the 
probability of a binary target acquiring an interest event of the assigned link function of 




one or more independent inputs. In our study, we used the cutoff value of 0.0014 from 
Rody et al. to average the crucial variables and assigned 1 to be BLBC class, and 0 for 
non-BLBC. 
After implementing these two types, the following models utilized: Artificial Neural 
Network, Logistic Regression, Decision Tree, Least Angle Regression, Bayesian 
Classifier, Gradient Boosting, Support Vector Machine, and Random Forest along with 
these nodes.                                                 
Result 
Performance Evaluation of the models 
A summary of the model’s performances on 22,000 gens of 579 TNBC cases used in this 
study is shown in Table 1 The table includes the misclassification, accuracy, sensitivity, 
and specificity rates for each classifier. According to the result, the neural network model 
shows the highest average accuracy compared to other methods. The Gradient Boosting 
and Logistics Regression models have very close values of accuracy, while the Decision 
tree has the lowest average accuracy.  
Table 1. Models' performance Evaluation. 
Feature Selection method: Chi-Square 
Method Misclassification Accuracy Sensitivity Specificity 
Decision Tree 0.0455 0.9545 0.9922 0.8542 
LARS 0.0511 0.9489 0.9766 0.8750 
Neural Network 0.0455 0.9545 0.9688 0.9167 
Logistics Regression 0.0398 0.9602 0.9688 0.9375 
SVM 0.0230 0.9770 0.9921 0.9362 
Gradient Boosting 0.0341 0.9659 0.9922 0.8958 
Random Forrest 0.0341 0.9659 0.9922 0.8958 
Bayesian Classifier 0.0520 0.9480 0.9680 0.8958 
Feature Selection method: Decision Tree 
Method Misclassification Accuracy Sensitivity Specificity 
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Decision Tree 0.0517 0.9483 0.9921 0.8298 
LARS 0.0345 0.9655 0.9764 0.9362 
Neural Network 0.0556 0.9444 0.9398 0.9574 
Logistics Regression 0.0287 0.9713 0.9843 0.9362 
SVM 0.0230 0.9770 0.9921 0.9362 
Gradient Boosting 0.0230 0.9770 0.9843 0.9574 
Random Forrest 0.0402 0.9598 0.9921 0.8723 
Bayesian Classifier 0.0575 0.9425 0.9528 0.9149 
Feature Selection method: LARS/LASSO 
Method Misclassification Accuracy Sensitivity Specificity 
Decision Tree 0.0625 0.9375 0.9922 0.7917 
LARS 0.0511 0.9489 0.9766 0.8750 
Neural Network 0.0118 0.9882 0.9918 0.9792 
Logistics Regression 0.0345 0.9655 0.9764 0.9362 
SVM 0.0455 0.9545 0.9844 0.8750 
Gradient Boosting 0.0172 0.9828 0.9921 0.9574 
Random Forrest 0.0455 0.9545 0.9844 0.8750 
Bayesian Classifier 0.0625 0.9375 0.9531 0.8958 
Feature Selection method: Principal Component Analysis 
Method Misclassification Accuracy Sensitivity Specificity 
Decision Tree 0.1207 0.8793 0.9606 0.6596 
LARS 0.0460 0.9540 0.9764 0.8936 
Neural Network 0.0345 0.9655 0.9764 0.9362 
Logistics Regression 0.0402 0.9598 0.9764 0.9149 
SVM 0.0517 0.9483 0.9843 0.8511 
Gradient Boosting 0.0805 0.9195 0.9685 0.7872 
Random Forrest 0.0707 0.9293 0.9781 0.7872 
Bayesian Classifier 0.1034 0.8966 0.9370 0.7872 
Feature Selection method: Multi-method 
Method Misclassification Accuracy Sensitivity Specificity 
Decision Tree 0.0862 0.9138 0.9606 0.7872 
LARS 0.0230 0.9770 0.9921 0.9362 
Neural Network 0.0172 0.9828 0.9843 0.9787 
Logistics Regression 0.0287 0.9713 0.9843 0.9362 
SVM 0.0287 0.9713 0.9843 0.9362 
Gradient Boosting 0.0172 0.9828 0.9921 0.9574 
Random Forrest 0.0230 0.9770 0.9921 0.9362 
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Bayesian Classifier 0.0230 0.9770 0.9843 0.9574 
 
The results indicate that most predictive models gained prediction accuracy from a multi-
method feature selection approach, compared to each individual approach. We found no 
evidence that a certain feature selection method is particularly well suited for use in 
combination with a specific predictive model. However, Decision tree, Gradient Boosting, 
Random Forest, and Bayesian Classifier did not gain much prediction accuracy from one 
principal component compared to another. 
 
The feature selection analysis revealed over 500 genes, which appear to be associated 
with BLBC. Table 2 summarizes the top 40 genes from pathways, which are associated 
with BLBC. These genes are sorted according to the number of times they were selected 
by the feature selection algorithms as input for predictive models..        
 
Table 2. Top 40 Genes Associated to BLBC. 
Gene Gene Description Count 
_205044_at Gamma-aminobutyric acid (GABA), A receptor, pi(GABRP) 14 
_220425_x_at ROPN1B 14 
_204855_at Serpin peptidase inhibitor, clade B (ovalbumin), member 5 (SERPINB5) 11 
_213260_at Forkhead box C1 (FOXC1) 11 
_205157_s_at Keratin 17, type I (KRT17) 10 
_209800_at keratin 16, type I (KRT16) 10 
_202037_s_at Secreted frizzled-related protein 1 (SFRP1) 9 
_206560_s_at Melanoma inhibitory activity (MIA) 9 
_209387_s_at Transmembrane 4 L six family member 1 (TM4SF1) 9 
_219768_at V-set domain containing T cell activation inhibitor 1 (VTCN1) 8 
_209504_s_at Pleckstrin homology domain containing, family B (evectins) member 1 
(PLEKHB1) 
7 
_211682_x_at UDP glucuronosyltransferase 2 family, polypeptide B28 (UGT2B28) 7 
_212236_x_at JUP 7 
_60474_at Fermitin family member 1 (FERMT1) 7 
_201820_at Keratin 5, type II (KER5) 6 
_208998_at Uncoupling protein 2 (mitochondrial, proton carrier) (UCP2) 6 
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_209126_x_at Keratin 6B, type II (KRT6B) 6 
_210473_s_at Adhesion G protein-coupled receptor A3 (ADGRA3) 6 
_202036_s_at Secreted frizzled-related protein 1 (SFRP1) 5 
_202504_at Tripartite motif-containing 29 (TRIM 29) 5 
_204751_x_at DSC2 4 
_213680_at Keratin 6B, type II (KRT6B) 4 
_217901_at Desmoglein 2 (DSG2) 4 
_218868_at ARP3 actin-related protein 3 homolog B (yeast) (ACTR3B) 4 
_200832_s_at Stearoyl-CoA desaturase (delta-9-desaturase) (SCD) 3 
_201485_s_at Reticulocalbin 2, EF-hand calcium binding domain (RCN2) 3 
_202342_s_at Tripartite motif containing 2 (TRIM 2) 3 
_203058_s_at 3'-phosphoadenosine 5'-phosphosulfate synthase 2 (PAPSS2) 3 
_204268_at S100 calcium binding protein A2 (S100A2) 3 
_205265_s_at SPEG complex locus (SPEG) 3 
_207397_s_at Homeobox D13 (HOXD13) 3 
_208063_s_at Calpain 9 (CAPN9) 3 
_209351_at Keratin 14, type I (KRT14) 3 
_209791_at Peptidyl arginine deiminase, type II (PADI2) 3 
_209842_at SRY (sex determining region Y)-box 10 (SOX10) 3 
_210074_at Cathepsin V (CTSV) 3 
_212147_at Nonsense mediated mRNA decay factor (SMGS) 3 
_214598_at Claudin 8 (CLDN8) 3 
_219301_s_at Contactin associated protein-like 2 (CNTNAP2) 3 
_219795_at Solute carrier family 6 (amino acid transporter), member 14 (SLC6A14) 3 
 
Neural Network (ANNs) 
Neural Network (ANNs) considered to be one of the powerful methods to analyze the 
data with high accuracy. In this study, this model identified 12 important genes that 
correlate with BLBC. Figure 1 shows the equation’s line between those gens and BLBC 
class. Those gens are Transglutaminase 2(TGM2), Discs, large homolog 5 
(Drosophila)(DLG5), Cytochrome b5 reductase 1(CYB5R1), Desmocollin 2(DSC2), 
Transmembrane protein 5(TMEM5), GDP-mannose 4,6-dehydratase(GMDS), Gamma-
aminobutyric acid (GABA) A receptor, pi(GABRP), Phospholipase A2, group IB 
(pancreas)(PLA2G1B), Junction plakoglobin(JUP), Chromosome 19 open reading frame 
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73(C19orf73), Rhophilin associated tail protein 1B (ROPN1B), and Nuclear factor I/X 
(CCAAT-binding transcription factor) (NFIX).  
 
Figure 3. Neural Network Model (ANNs). 
In Figure 3, the small blue circles on the far left of the link graph represent all variables 
input (genes), which have correlation with BLBC. The target variable placed on the far 
right of the link graph; which is in this case represents class=1 (the BLBC subtype). H1, 
H2, and H3 are the hidden layers. The color and the width of the linked lines indicate 
how secure the connection is of that particular line; the thinner, blue lines represent a 
smaller value of the weight of that connection, and the thicker red line indicates a 
substantial magnitude value of the link connection.83 
In Figure 3, chromosome 19 open reading frame 73(C19orf73), phospholipase A2, group 
IB (pancreas)(PLA2G1B), and GDP-mannose 4,6-dehydratase(GMDS) have pink and 
thicker lines, which means that the magnitude of the weight of the connection is 




significant. These genes linked to hidden “layer 3” (H3); H3 linked to class=1 (BLBC) by 
the red, thicker line, which shows a strong connection. As a result, C19orf73, PLA2G1B, 
and GMDS have a higher correlation to BLBC, followed by CYB5R1 and JUP.  
 
These 12 genes are known to be involved in various aspects of TNBC’s pathogenesis. For 
instance, TGM2 is involved in TNBC epithelial-to-mesenchymal transition (EMT), which 
promotes their migratory and invasive properties, and controls their chemoresistance and 
immune escape.84 In addition, TGM2 expression is frequently up-regulated during 
inflammation and wounding. Emerging evidence indicates that TGM2 expression is 
aberrantly up-regulated in multiple cancer cell types, particularly those selected for 
resistance to chemotherapy and radiation therapy and those isolated from metastatic site.85 
 
Loss of DLG5 promotes TNBC cell proliferation by inhibiting the Hippo signaling 
pathway, increasing nuclear YAP expression, and inducing EMT.86 DLG5 plays important 
roles in epithelial cell polarity maintenance, precursor cell division, cell proliferation, cell 
migration and invasion, and transmission of extracellular signals to the membrane and 
cytoskeleton. Failure in establishment and maintenance of epithelial cell polarity 
contributes to tumorigenesis. Loss of expression and function of cell polarity proteins is 









directly related to epithelial cell polarity maintenance.87 Another gene whose expression 
correlates with EMT is CYB5R1, which is a widely expressed oxidoreductase involved in 
oxidative stress reactions and drug metabolism. Although its specific role in cancer 
progression is still not clear, its transcriptional level expression strongly correlates with 
EMT in colorectal cancer.88  
The DSC2 protein is a major component of desmosomes, which provide strength and 
stability to tissues. This protein has been shown to be highly expressed in TNBCs, being 
able to significantly predict patient survival, and suggesting their role in the aggressiveness 
seen in these tumors.89 TMEM5 is a type II transmembrane protein, thought to be a 
glycosyltransferase involved in the glycosylation of dystroglycan, which is part of a 
complex that links the extracellular matrix to the cytoskeleton. Aberrant glycosylation 
leads to the disruption of this link thus favoring migration and invasiveness seen in many 
tumors.90 TMEM5 is significantly over-expressed in BRCA1-mutated breast cancer cells,91 
with these type of mutations occurring in TNBC more frequently than in the general 
population,92 93. GMDS is involved in the process of cellular fucosylation of glycoproteins, 


















which involved in the functional regulation of adhesion molecules and growth factor 
receptors, with high levels of fucusylation being reported in various types of cancer.94 This 
has been associated with TNBC and EMT, making GMDS a potential player in this 
process.95 
Expression of GABRP is shown to be associated with the BLBC/TN subtype, and herein, 
we reveal its expression also correlates with metastases to the brain and poorer patient 
outcome.96 PLA2G1B are esterases that preferentially cleave glycerophospholipids into 
biologically active fatty acids and lysophospholipids, and are differentially expressed in 
breast cancer.97 These active lipids have biological functions relevant to cancer progression 
and each can be further metabolized into additional functional biomolecules.98 These active 
lipids modulate cellular differentiation, proliferation, apoptosis and senescence, whose 
dysregulation can result in the uncontrolled growth and metastasis seen in tumors.  
JUP is a cell adhesion protein, was recently reported as a determinant of circulating tumor 
cells types, single or clustered. This protein could be functioning as a double-edge sword, 
since loss of its expression leads to increased motility of epithelial cells, thereby promoting 
EMT and further metastasis. However, studies also show that JUP can function as an 
oncogene, with high expression of JUP resulting in clustered tumor cells in circulation with 
high metastatic potential in breast cancer and shortened patient survival. In addition, JUP 












may be a potential prognostic biomarker that can be exploited to develop as a therapeutic 
target for breast cancer.99 Although C19orf73 is a hypothetical protein that has not been 
characterized, a search of the GEO Profiles database100 revealed that it is overexpressed in 
TNBC (GEO accession GDS4069.101 
Ropporin is a sperm-specific protein and is associated with sperm motility. Its expression 
was also found in motile cilia helping them to move in one direction in a synchronized 
pattern. Ropporin (ROPN1 and ROPN1B) was identified as differentially-expressed in 
several gene lists commonly associated with bad prognosis in our breast cancer 
investigation.102 The Nuclear Factor I (NFI) family of site-specific DNA binding 
proteins functions in adenoviral DNA replication and in the regulation of transcription of 
a large variety of cellular and viral genes. This family is comprised of four genes in 
vertebrates (NFIA, NFIB, NFIC and NFIX), whose encoded proteins interact with DNA as 
homo- or hetero-dimers. They bind to the palindromic sequence TTGGC(N5)GCCAA with 
high affinity, resulting in transcriptional activation or repression, depending on the cellular 
context and regulatory region . Binding sites for these factors have been identified 
in promoter, enhancer and silencer regions of a plethora of genes expressed in almost every 








organ and tissue.103 It’s been found that expression is increased in TNBC across the datasets  




Logistic regression is another technique that we used in this analysis. In figure 4, the 
chart shows the relative importance to BLBC for 12 genes sorted in descending order. 
The horizontal axis is the correlated genes, while the vertical axis shows the value of the 
correlation range from 0-1 since the binary targets have two levels, where 1 represents 
the essential variables.   
According to the results, gamma-aminobutyric acid (GABA) A receptor, pi (GABRP), 
has the highest correlation with BLBC based on the relative importance value; followed 
by JUP, ROPN1B, DSC2, TMEM5, GMDS, NFIX, C19orf73, DLG5, CYB5R, 
PLA2G1B, and TGM2, respectively. 















The decision tree model shows gene expressions in ascending order regard on the 
correlation to BLBC subtype. Each node includes some general properties such as the 
node Id, statistic information for both the train and validation group. As mentioned 
earlier, 1 represents the BLBC class and 0 for the non-BLBC class.  
In figure 5, Node 1 represents gamma-aminobutyric acid (GABA) A receptor, 
pi(GABRP) as the highest correlated gene to BLBC; reflecting that a 72.73% of TNBC 
classified as BLBC in the validation group, and 27.27% are non-BLBC. On the other 
hand,72.95% are BLBC of the training group, and 27.05% are non-BLBC. However, two 
split nodes resulted according to the rule of “if values are less or more than the cutoff 
value (0.0014)”. The corresponding genes are given in Table 3. However, based on a 
research was done to investigate the impact of gene expression on TNBC, all these 
identified genes were up-regulated in TNBC (more details are discussed in discussion 
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section). Therefore, it can not be concluded if any up or down regulation is associated 
with TNBC from discussion model.  
Table 3. Gene importance by Decision Tree model. 
Gene  Importance  Description  
GABRP 1 gamma-aminobutyric acid (GABA) A receptor, pi. 
JUP  0.5097 junction plakoglobin. 
ROPN1B 0.4033 rhophilin associated tail protein 1B. 
DSC2 0.3393 desmocollin 2. 
TMEM5 0.2383 transmembrane protein 5.  
 
 
Figure 5. Decision Tree model. 
Discussion tree algorithm, started single node by classifying GABRP gene as most 
important gene with score 1 out of 1 as shown in table 3. Then it branches to other 
possible classification based on the average importance value. Therefore, if it less than 
0.0041 the second important gene is JUP gene as single node 2, from node 2 at average of 
0.0093 another node branched to predict another relevant gene which is ROPN1B. at 
each node the statistical information is provided as mentioned before.  
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Random Forest    
 
Random Forest model targeted 10 genes. Table 4 includes the number of splitting rules 
for each gene. However, As the rules splits more, the importance of the gene increases. 
Some genes have the same number of splitting rules, which means that those genes have 
the same level of importance.  
Table 4. Random Forest with variable selection enabled. 
Variable Name Number of splitting rules Gene 
_202504_at 15.0 TRIM 29 
_205157_s_at 12.0 KRT17 
_202342_s_at 9.0 RCN2 
_204855_at 9.0 SERPINB5 
_206560_s_at 9.0 MIA 
_214404_x_at 8.0 SPDEF 
_219615_s_at 8.0 KCNK5 
_202431_s_at 7.0 MYC 
_205044_at 7.0 GABRP 
_209504_s_at 6.0 PLEKHB1 
 
Table 4 ranked the most important gene as following: TRIM2, Keratin 17, type I 
(KRT17), Reticulocalbin 2, EF-hand calcium binding domain (RCN2), Serpin peptidase 
inhibitor, clade B (ovalbumin), member 5 (SERPINB5), Melanoma inhibitory activity 
(MIA), SAM pointed domain-containing Ets transcription factor (SPDEF), Potassium 
channel subfamily K member 5 (KCNK5), Proto-Oncogene, BHLH transcription factor 
(MYC), GABRP, then Pleckstrin homology domain containing, family B (evectins) 
member 1 (PLEKHB1).  
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Least Angle Regression 
  
Figure 6 represents Least angle regression model; the method estimates the correlation 
between the gen and BLBC. The blue bars represent a positive correlation with BLBC, so 
the highest gene expression estimates, the highest chance to be classified as BLBC. The 
red bars represent a negative correlation with BLBC. However, UDP 
glucuronosyltransferase 2 family, polypeptide B2(UGT2B28), and cytoplasmic linker 
associated protein 1(LASP1) have a negative correlation with BLBC. 
 
 
Figure 6 Least angle regression model. 
 
In figure 6, the most critical genes based on the estimated value, are sorted in ascending 
order as following: ROPN1B, Forkhead box C1 (FOXC1), GABRP, Secreted frizzled-
related protein 1 (SFRP1), keratin 16, type I (KRT16), SERPINB5, PLEKHB1, KRT17, 
MIA, Fermitin family member 1 (FERMT1), V-set domain containing T cell activation 
inhibitor 1 (VTCN1), Keratin 5, type II (KRT5), Keratin 6B, type II (KRT6B), 
Desmoglein 2 (DSG2), Vestigial like family member 1(VGLL1), following by EPH 





Bayesian Classifier is another method used to analyze the data. This model shows the genes 
most relevant to BLBC. The result of this model is represented in Table 5, where the most 
important 12 genes are presented.  
Table 5. Gene Ranking (importance) using Bayesian Classifier. 
Variable Name of the gene Order Score 
_220425_x_at ROPN1B 1.0 -149.8388379843322 
_205044_at GABRP 2.0 -152.06028382414326 
_212236_x_at JUP 3.0 -178.30128029698253 
_204751_x_at DSC2 4.0 -197.10605719691765 
_204875_s_at GMDS 5.0 -250.02823043246084 
_202263_at CYB5R1 6.0 -252.2041273457195 
_222339_x_at NFIX 7.0 -255.19927200917277 
_201042_at TGM2 8.0 -256.2482325776195 
_220151_at C19orf73 9.0 -257.503065161863 
_201681_s_at DLG5 10.0 -260.21558211552104 
_206311_s_at PLA2G1B 11.0 -261.0894822749076 




Gradient Boosting is the model with the highest accuracy performance in this study 
(97.15%). This model shows 12 most important genes, which have a high correlation with 
BLBC, as shown in Table 6. According to the results, ROPN1B is the most important gene 



















_220425_x_at ROPN1B 220425_x_at 24 1 1 1 
_205044_at GABRP  205044_at 13 0.976866 0.843971 0.863958 
_212236_x_at JUP 212236_x_at 20 0.6846 0.570677 0.833592 
_204751_x_at DSC2 204751_x_at 7 0.403207 0.437559 1.085197 
_201042_at TGM2  201042_at 3 0.093932 0 0 
_201681_s_at DLG5 201681_s_at 2 0.093776 0 0 
_202263_at CYB5R1  202263_at 2 0.084822 0 0 
_204808_s_at TMEM5 204808_s_at 2 0.062419 0 0 
_220151_at C19orf73  220151_at 1 0.061109 0.060705 0.993387 
_222339_x_at NFIX 222339_x_at 2 0.059511 0 0 
_206311_s_at PLA2G1B 206311_s_at 1 0.032846 0 0 





Table 7 shows all the relevant genes to BLBC with the model’s names since some genes 
resulted as having association with BLBC in more than two models. The table helped to 
identify the most important genes. Since each model has a unique algorithm to classify 
those genes, the probability of the identifying the most correlated genes will high. 
Table 7. Gene’s list with models. 
Gene Models 
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ROPN1B Neural Network, Logistic Regression, Decision Tree, Least Angle 
Regression, Bayesian classifier, Gradient Boosting. 
GABRP Neural Network, Logistic Regression, Decision Tree, Random Forest, 
Least Angle Regression, Bayesian classifier, Gradient Boosting. 
TGM2 Neural Network, Logistic Regression, Bayesian classifier, Gradient 
Boosting. 
JUP Neural Network, Logistic Regression, Decision Tree, Bayesian 
classifier, Gradient Boosting. 
DSC2 Neural Network, Logistic Regression, Decision Tree, Bayesian 
classifier, Gradient Boosting. 
TMEM5 Neural Network, Logistic Regression, Decision Tree, Bayesian 
classifier, Gradient Boosting. 
GMDS Neural Network, Logistic Regression, Bayesian classifier, Gradient 
Boosting. 
CYB5R1 Neural Network, Bayesian classifier, Gradient Boosting. 
DLG5 Neural Network, Logistic Regression, Bayesian classifier, Gradient 
Boosting. 
PLA2G1B Neural Network, Logistic Regression, Bayesian classifier, Gradient 
Boosting. 
C19orf73 Neural Network, Logistic Regression, Bayesian classifier, Gradient 
Boosting. 
NFIX Neural Network, Logistic Regression, Bayesian classifier, Gradient 
Boosting. 
TRIM 29  Random Forest  
KRT17 Random Forest, Least Angle Regression. 
RCN2 Random Forest 
SERPINB5 Random Forest, Least Angle Regression. 
MIA 
PLEKHB1 
Random Forest, Least Angle Regression. 
Random Forest, Least Angle Regression. 
SPDEF Random Forest 
KCNK5 Random Forest 
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MYC Random Forest 
KRT16 Least Angle Regression 
FERMT1  Least Angle Regression. 
VTCN1  Least Angle Regression. 
DSG2 Least Angle Regression. 
KRT6B  Least Angle Regression. 
EPHB3 Least Angle Regression. 
VGLL1 Least Angle Regression. 
SERP1 Least Angle Regression. 
FOXC1  Least Angle Regression. 
KRT5  Least Angle Regression. 
 
Discussion	
Based on the results, ROPN1B and GABRP are the most correlated genes where 
ROPN1B shows as the most relevant gene to BLBC both in Gradient Boosting and 
Bayesian models with the average of 96.01% accuracy, and third associated gene in 
Logistic regression and Decision tree with average of 95.87% accuracy. GABRP also is a 
robust, relevant gene to BLBC; it is the first important gene in both Logistic regression 
and Decision tree with an average of 95.87% accuracy, and the 2ed in Gradient Boosting 
and Bayesian models with average of 96.01% accuracy. However, the Gradient Boosting 
model shows the highest accuracy of 0.971591 compared to other methods.  
We systematically searched the web of science databases, PubMed, and Journals to 
identify studies which support our results. Table 8 represents the relevant studies for each 
gene. In the included studies, the expression of ROPN1B, GABRP, JUP, DSC2, 
TMEM5, PLA2G1B, TRIM 29, RCN2, EPHB3, SERPINB5, MIA, SPDEF, KCNK5, 
MYC, KRT5, KRT16, KRT6B, KRT17, FERMT1, EPHB3, VGLL1, SFRP1, and 
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FOXC1 were up-regulated in breast cancer as general while the down-regulated 
CYB5R1, DLG5, and C19orf73 expressions were associated with BC. 
Table 8. Gene’s list with relevant studies supports our results. 
Gene Relevant studies  
ROPN1B According to Jai Mehta study105, ROPN1B was significantly up-
regulated in breast cancer patients who relapsed, BC patients who did not 
survive for more than five years, BC patients who relapsed within five 
years, and patients with negative Estrogen Receptor tumors. Besides, 
ROPN1B up-regulated in a sub-group of ER-negative BC with a high 
incidence of relapse. Another study106 also reported an up-regulated 
expression of ROPN1B in ER-/HER2- BC tumors. However, It is it is 
crucial to investigate the role of ROPN1B in BC since little is known 
about this protein. 
GABRP According to another study107, about decade ago, GABRP expression 
was reported to correlate with BLBC. Moreover, GABRP gene not only 
correlates with BLBC, but also correlated with metastatic dissemination 
to the brain, showing poorer prognosis. They reported that silencing 
GABRP in BLBC cells decreased migration, BLBC-associated 
cytokeratins, and ERK1/2 activation. Furthermore, GABRP expression 
was up-regulated in ER-/HER2- BC tumors based on Bioinformatics 







analysis.108 Therefore, knocking down GABRP expression may be a new 
approach for BLBC treatment.109 
TGM2 Tissue-type transglutaminase 2(TGM2) is a pro-inflammatory protein 
associated with the resistance of drugs and the metastatic phenotype in 
BC. TGM2 reported110 as an essential link in interleukin (IL)-6 mediated 
cancer cell aggressiveness, it is also an important mediator of distant 
metastasis. Suppressing TGM2 appears to increase the chemo-sensitivity 
of cancer cells that were treated with drugs and could be a therapeutic 
approach.111 
JUP an investigation112 for breast cancer survival and Plakoglobin (JUP) was 
done by using multivariate and univariate analyses. JUP might be a 
function of a double-edged sword molecule. Decrease in JUP expression 
causes an increase of motility of epithelial cells. Therefore, epithelial-
mesenchymal transition is prompted and further cancer metastasis. The 
same study shows that JUP is an oncogene function. High JUP 
expression causes in clustered tumor cells with high metastatic potential 
in BC and reduces the probability of patient survival.	 











DSC2 The DSC2 protein is a major component of desmosomes, which provides 
strength and stability to tissues. A study113 of gene expression microarray 
analysis was performed by unsupervised hierarchical clustering to 
identify relevant genes that was expressed differentially between BLBC 
and non-BLBC. The results show that DSC2 overexpressed in the TNBC 
subtype.  
Furthermore, DSC2 is a part of a six-gene signature that predicts 
metastasis of BC lung.114 A later study115 has been reported that DSC2 is 
associated with BLBC. This protein has been shown to be highly 
expressed in TNBCs, being able to significantly predict patient survival, 
and suggesting their role in the aggressiveness seen in these tumors.116  
TMEM5 TMEM5 significantly up-regulated in BRCA1, it expressed about three 
times more in BRCA1 mutated cell line (SL) compared to BRCA1 wild-
type cell line (BS). 117 118 
PLEKHB1 PLEKHB1 known also as KPL-1and KP-1 is a human breast cancer cell 
line based on the malignant effusion of a patient with breast cancer.119 














GMDS   GMDS is involved in the process of cellular fucosylation of 
glycoproteins, which is involved in the functional regulation of adhesion 
molecules and growth factor receptors, with high levels of fucusylation 
being reported in various types of cancer.120 This has been associated 
with TNBC and EMT, making GMDS a potential player in this 
process.121 
CYB5R1 Estrogen-related receptor alpha (ERRα) is overexpressed in different 
types of tumors, including breast tumors (tripe-negative breast cancer). It 
is associated with more aggressive tumors, worse outcomes, and 
increased rate of recurrence.122 Taken together with another study123 
suggested that CYB5R1 was significantly down-regulated based on 
microarray analysis of ERRα-silenced HCT116 cells. Along with our 
results, we suggest that CYB5R1 may correlate with TNBC, Basal-like 
breast cancer. 
DLG5 DLG5 is another gene that correlated with BLBC whose loss of expression 
resulted in Hippo pathway inhibition through the induction of Scribble 
mislocalization and down regulating its expression. Also, loss of DLG5 
leads to increasing  Yes-associated protein(YAP) nuclear localization; in 
summary, loss of DLG5 expression promoted breast cancer malignancy so 









a more effective tumor therapy can be achieved by over expression of 
DLG5.124 This study along with previous studies show that DLG5 acts 
as a tumor suppressor in breast cancer125, and its expression is up-regulated 
in BLBC according  to our study. 
PLA2G1B The overexpression of PLA2G1B is associated with a high level of 
Choline. However, a high level of Choline and Phosphocholine have 
been demonstrated in BC cells. Worth to mention, most of the xenograft 
models were BLBC.126 
C19orf73 Huayan et al.127 examined the integrin β4 expression in breast tumors, 
and its function in cancer stem cells regulation. As it is known that 
integrin β4 contributes to BC tumors in terms of invasion, formation, and 
metastasis. According to her data, β4 expression expressed 
heterogeneously in BC; but not directly expressed in cancer stem cells 
but correlated with the population of basal epithelial. However, c19orf73 
observed as down-regulated in β4 knockout cells.  
NFIX A study128 used a DNA methylation MIRA microarray analysis to 
identify biomarkers for early detection of BC. According to their results, 












NFIX was one of three genes that was first identified to be 
hypermethylated in BC.  
TRIM 29  A study reported that an overexpression of exogenous microRNA-761 
amplified the TNBC cell proliferation, migration, invasion, and colony 
formation in vivo. MicroRNA-761 represses TRIM29 expression, 
inducing aggressive phenotypes in TNBC cells. However, the 
overexpression of TRIM29 reversed the TNBC cell proliferation and 
invasion.129 TRIM29 may act as a regulatory factor in cancer tumors. In 
support of this research, a recent study had been reported that the up-
regulated of TRIM29 expression is associated with ER-/HER2- BC 
tumors.130 Using TRIM29, there needs to be  more studies conducted in 
breast cancer cells because TRIM29 suppresses invasiveness by down-
regulating the expression of TWIST1, whereas TRIM29 promotes cell 
invasion by regulating MMP-9 in lung cancer.131 
RCN2 RCN2 indicated in many reports an up-regulated in various types of 
cancer tumors including breast, colorectal, kidney, and liver cancer.132 
SERPINB5 
(MASPIN) 
Many studies claim that the loss of SERPINB5 expression is associated 
with breast cancer. One of the studies133 reported that the epithelial gene 










SERPINB5 significantly inhibited cell motility. Another report134 
suggested that SERPINB5 has involved in determining the metastatic 
potential of BC cell lines. Furthermore, SERPINB5 expression was 
reported to correlate with BLBC rather than to be a myoepithelial 
markers in TNBC. MASPIN may play a substantial role in regulating 
processes that are associated with the progression and metastatic cascade 
of TNBC and could present an exclusive and specific target for the 
diagnosis and therapeutic intervention of TNBC. 
MIA (MIA) is known as a small secreted protein expressed in cartilage; a recent 
study reported that it is overexpressed in breast cancer.135In situ expression 
patterns study136, MIA expression has been observed at higher levels in 
breast cancer and reported to have a much bolder expression in 
malignant epithelial neoplasm. A recent study supports the correlation 
link between MIA and TNBC by reporting an overexpression of MIA in 




Androgen receptor expression overexpressed in approximately 70% of 
breast cancer. SPDEF is one of the Androgen receptor-related genes, 
which reported as overexpressed in molecular apocrine tumors.138 
However, PDEF expression restricted to epithelial cells in the breast.139  











KCNK5 Overexpression of KCNK5 has been observed to have a significant 
correlation with TNBC; however, it failed to meet the significance 
criteria to be relevant to BLBC.140 Conversely, Clarker et al. suggested 
that up-regulated KCNK5 expression is associated with poor outcomes in 
BLBC.141  
MYC Based on Immunohistochemical analysis,142 high expression of MYC 
was reported to associate with the BLBC tumor subtype. Furthermore, 
other studies of the transformation of epithelial cells show the correlation 






KRT5, KRT16, KRT6B and KRT17 are early detection biomarkers for 
TNBC tumors known as Basal-like cytokeratins.145 A recent 
investigation146 found that KRT6B, KRT16, KRT17, and KRT81 were 
up-regulated and correlated with cancer cell proliferation and invasion 
pathways. Further support of the link between KRT16 and BLBC, a 

















study147 of circulating tumor cells reported that overexpression of 
KRT16 in BLBC cell lines was associated with shorter relapse-free 
survival.  
FERMT1  Based on bioinformatics analysis from microarray data, FERMT1 up-
regulated in ER-negative/HER2-negative breast cancer tumors.148 
Another study149 reported that FERMT1 was predictive of BC lung 
metastases, which in gene expression of 23 metastases of BC tumors 
were analyzed. 
VTCN1  A report150 suggests that VTCN1 expression was significantly different 
in BC tumors compared to normal tumors, which may be involved in the 
progression of BC and metastasis. Also, they suggested that VTCN1 
expression could be an early-biomarker for BC.  
DSG2 DSG2 expression was reported to present in the invasion and motility of 
BC cells; also, it may act as a tumor suppressor molecule.151 
EPHB3 Ephrin B receptors are associated with complex signally pathways in 
cancer. A study conducted by using microarray data for 3,554 patients 
had reported that overexpression of EPHB3 was significantly associated 
with worse survival in BC patients. From the same study findings, 











EPHB3 was also reported to have an association with the improvement 
of relapse-free survival with BLBC.  
VGLL1 According to bioinformatics analysis results, Overexpression of VGLL1 
associated with ER-negative/HER2-negative breast cancer.152 
SFRP1 SFRP1 has been suggested to be a potential prognostic marker153 . 
Moreover, an increased secretion of this protein has correlated with 
higher expression in BLBC cell lines. Furthermore, an study showed that 
SFRP1 strongly correlates with the TNBC subtype and that SFRP1 might 
be used as a marker classifying patients to positively respond to 
neoadjuvant chemotherapy.154 
PADI2 PADI2 expression correlates with breast cancer, where PADI2 
expression contributes to migration of abnormal in breast cancer tumor 
cells.155 
HOXD13 It is related with positive LNM and tumor size in breast cancer. In 
addition, low levels of HOXD13 correlates with poorer survival in breast 
cancer patients.156 












TM4SF1 A high level of TM4SF1 was shown in TNBC tissues, suggesting that 
TM4SF1 might be a biomarker of TBNC.157 
FOXC1  A higher level of FOXC1 expression boosts TNBC metastasis by 
activating the transcription of CXRC4. However, in a zebrafish tumor, 
either siRNA or AMD3100 in MDA-MB-231 cells can inhibit CXRC4 
by down-regulated FOXC1.158 According to an analysis of microarray 
data sets for 2,073 breast cancer patients, FOXC1 suggested to be a 
diagnostic and prognostic biomarker, and could be used as a therapeutic 
target for the BLBC subtype.159 FOXC1 is a desirable avenue for further 
research as a possible therapeutic target in cancer treatment using 
nanomedicine. 
Another study shows that UGT2B28 expression in a breast cancer cell line, suggests its 
role in androgen and estrogen metabolism.160 There is currently no study showing a 
correction between UGT2B28 and the TNBC subtype. According to related studies, 
UCP1, 2 and 3 act as inductors for autophagy and mitochondrial dysfunction in breast 
cancer cells, which cause a significant reduction in tumor growth.161 However, as with 













UGT2B28, there are no published results available to support UPC2’s correlation with 
either TNBC or BLBC. 
Conclusions 
 
Triple-negative breast cancer (TNBC) constitutes approximately 20%-25% of all breast 
cancer cases with poor prognoses, with Basal-like breast cancer (BLBC) being a subtype 
representing 72.8% of TNBC. Classifying BLBC subtypes is of paramount importance for 
proper diagnosis, with direct clinical implications by dictating the most effective course of 
treatment.  
Although prior research has shown that profiling breast cancers using gene expression 
data has been useful in investigating and defining prognosis and therapy, little attention 
has been paid to the molecular characteristics of the basal-like group of breast cancers. 
Most (if not all) microarray studies of BLBC have been based on small sample size and 
conducted in isolation from one another in most cases, thus limiting the generalizability 
of the results. To illustrate the significance of data integration in microarray gene 
profiling of basal-like breast cancers. in this study, we combined over 24,000 genes of 
579 TNBC patients from several TNBC gene expression datasets to identify several 
important gene signatures in BLBC. A series of different predictive models were built to 
analyze the data with acceptable accuracy rates.  The high dimensionality of the resultant 
dataset negatively affected the models’ performance due to overfitting. To address this 
issue, several feature selection algorithms were applied to the combined microarray data 
in order to identify informative genes for building predictive models. Our results show 
the usefulness of data integration in finer understanding of gene expression in basal-like 
breast cancers. In addition, a combination of data mining and feature selection techniques 
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allow new genes related to basal-like breast cancers to be identified from many data 
sources that may be otherwise difficult to detect. In particular, our results showed that the 
most important genes that correlate with BLBC are ROPN1B and GABRP, SERPINB5, 
FOXC1, KRT16 and KRT17. Our analysis provided new insights into the pathways 
in the basal-like group of breast cancers which need to be further investigated in order to 
develop BLBC specific treatments. The primary focus of different therapeutic approaches 
for cancer treatment is cancer cells apoptosis. Nanomedicines may be the treatment of 
choice for all the different types of cancer due to their excellent efficacy in penetration, 
specific retention and killing of tumor cells. However, the success of nanomedicine is the 
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